Walter M. Stadler to Clinical Trials as Topic
This is a "connection" page, showing publications Walter M. Stadler has written about Clinical Trials as Topic.
Connection Strength
1.699
-
There Is More to Length of Survival Than Survival: Endpoints in Oncology Trials. Clin Cancer Res. 2024 Aug 01; 30(15):3098-3099.
Score: 0.648
-
New trial designs to assess antitumor and antiproliferative agents in prostate cancer. Invest New Drugs. 2002 May; 20(2):201-8.
Score: 0.138
-
Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5.
Score: 0.130
-
Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
Score: 0.119
-
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016 Apr 20; 34(12):1402-18.
Score: 0.090
-
Pazopanib in renal cell carcinoma. Clin Cancer Res. 2010 Dec 15; 16(24):5923-7.
Score: 0.063
-
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res. 2010 Mar 15; 16(6):1745-55.
Score: 0.060
-
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. Clin Genitourin Cancer. 2008 Dec; 6 Suppl 1:S22-8.
Score: 0.055
-
Recommended changes to oncology clinical trial design: revolution or evolution? Eur J Cancer. 2008 Jan; 44(1):8-11.
Score: 0.051
-
Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development. Clin Cancer Res. 2007 Mar 15; 13(6):1630-3.
Score: 0.049
-
Sorafenib. Curr Opin Oncol. 2006 Nov; 18(6):615-21.
Score: 0.047
-
New targets, therapies, and toxicities: lessons to be learned. J Clin Oncol. 2006 Jan 01; 24(1):4-5.
Score: 0.044
-
Novel kinase inhibitors in renal cell carcinoma: progressive development of static agents. Curr Oncol Rep. 2005 Mar; 7(2):116-22.
Score: 0.042
-
Optimizing the doses of cancer drugs after usual dose finding. Clin Trials. 2024 Jun; 21(3):340-349.
Score: 0.039
-
Angiogenesis inhibitors in genitourinary cancers. Crit Rev Oncol Hematol. 2003 Jun 27; 46 Suppl:S41-7.
Score: 0.038
-
Angiogenesis inhibitors. Curr Oncol Rep. 2000 Jan; 2(1):11-6.
Score: 0.029
-
Gemcitabine and other new chemotherapeutic agents for the treatment of metastatic bladder cancer. Urology. 1999 Feb; 53(2):243-50.
Score: 0.028
-
Integration of neoadjuvant and adjuvant chemotherapy and cystectomy in the treatment of muscle-invasive bladder cancer. BJU Int. 2008 Nov; 102(9 Pt B):1339-44.
Score: 0.014
-
Activities and accomplishments of the cancer and leukemia group B genitourinary committee. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3596s-600s.
Score: 0.011
-
The cure of bladder cancer: the need for multidisciplinary efforts. J Urol. 1994 Mar; 151(3):605-6.
Score: 0.005